Physician profile
Christopher Wiegand
NPI 1780767137
$3,948.43
in general payments reported to CMS, 2019-2025
21 companies · $808 in 2025
The $808 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $469 · 2021: $598 · 2022: $460 · 2023: $503 · 2024: $796 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $874.89 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $592.18 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $365.13 | 2019-2024 | Rexulti, Abilify Asimtufii, Nuedexta |
| Neurocrine Biosciences, INC. | $354.52 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $354.15 | 2019-2025 | Spravato, Invega Sustenna, Invega |
| Takeda Pharmaceuticals U.S.A., INC. | $265.25 | 2019-2025 | Trintellix |
| Lundbeck LLC | $242.20 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.26 | 2020-2025 | Caplyta |
| Allergan, INC. | $160.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $121.64 | 2020-2025 | Fanapt |
| Alkermes, INC. | $87.40 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $65.79 | 2023-2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $65.57 | 2023-2025 | Quviviq, Quviviq |
| Eisai INC. | $58.72 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.33 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $19.37 | 2019 | |
| Alfasigma USA, INC. | $17.07 | 2021 | |
| Almatica Pharma LLC | $15.92 | 2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $14.74 | 2021 | |
| Bioxcel Therapeutics, INC. | $13.65 | 2025 | Igalmi |
| Bausch Health US, LLC | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wiegand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.